Merck (MRK) Cash & Equivalents (2009 - 2026)

Merck (MRK) has reported Cash & Equivalents for 18 consecutive years, with $5.3 billion the latest figure, recorded in Q1 2026.

• In Q1 2026, Cash & Equivalents fell 38.27% year-over-year to $5.3 billion; the TTM figure through Mar 2026 stood at $5.3 billion (down 38.27% YoY), while the FY2025 annual figure was $14.6 billion, up 9.99% from the prior year.
• Cash & Equivalents retreated to $5.3 billion in Q1 2026 per MRK's latest filing, from $14.6 billion in the prior quarter.
• Across five years, Cash & Equivalents topped out at $18.2 billion in Q3 2025 and bottomed at $5.3 billion in Q1 2026.
• Historically, Cash & Equivalents has averaged $10.1 billion across 5 years, with a median of $9.7 billion in 2022.
• Annual changes were most pronounced in 2023 — Cash & Equivalents plunged 46.11% — and 2024, when it soared 99.72%.
• Merck's Cash & Equivalents stood at $12.7 billion in 2022, then slumped by 46.11% to $6.8 billion in 2023, then soared by 93.57% to $13.2 billion in 2024, then increased by 9.99% to $14.6 billion in 2025, then slumped by 63.43% to $5.3 billion in 2026.
• Business Quant data shows MRK's Cash & Equivalents at $5.3 billion in Q1 2026, $14.6 billion in Q4 2025, and $18.2 billion in Q3 2025.